Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Announcement under Regulation 30 (LODR)-Acquisition

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') it is hereby informed that Krishna Institute of Medical Sciences Limited ('Company'), has entered into a share purchase agreement ('SPA') and shareholders agreement ('SHA'), each dated 27.10.2021, with the existing promoter and certain other shareholders of Sarvejana Healthcare Private Limited (Sunshine Hospitals) ('Target Company') to acquire 51.07% of the equity share capital of the Target Company (as a combination of 18.52% stake through equity shares and the remainder through partly paid-up equity shares, which shall be fully paid up by April 2022 based on agreed schedule).
27-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October 21, 2021 for Bollineni Seenaiah Naidu
22-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 21, 2021 for Bollineni Seenaiah Naidu
22-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Shareholding for the Period Ended September 30, 2021

Krishna Institute of Medical Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here
19-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Statement Of Investor Complaints For The Quarter Ended September 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 062620 Name of the Signatory :- Mr Umashankar ManthaDesignation :- Company Secretary and Compliance Officer
12-10-2021

This pharma stock has doubled investors' money in a year. Axis Securities' recommends as top pick

Gland Pharma and KIMS are the domestic and research brokerage firm's top stock picks in the pharma sector
11-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October 08 for Bhaskara Rao Bollineni
08-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 08 for Bhaskara Rao Bollineni
08-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September, 2021
08-10-2021
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Closure of Trading Window

Company intimates exchange about Closure of Trading Window.
29-09-2021
Next Page
Close

Let's Open Free Demat Account